There are now five targeted agents, ie sorafenib, sunitinib, temsirolimus, bevacizumab (in
combination with interferon) and everolimus, that have been shown to improve the outcome …

Renal cell carcinoma (RCC) is an umbrella term for a collection of vastly different
malignancies originating in the kidney, with varying prognosis and clinical behavior. On the …

Materials and Methods: A systematic review of the literature was performed according to the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines …

The therapeutic landscape for advanced clear cell renal cell carcinoma (ccRCC) is rapidly
evolving with improved knowledge of the biology of disease leading to the incorporation of a …

Objectives The optimal treatment strategy for metastatic non‐clear cell renal cell carcinoma
(mNCCRCC) is still elusive and mainly extrapolated from evidence available for metastatic …

Advanced renal cell carcinoma (RCC) is a heterogeneous disease with variable histology,
biology, and response to treatment. In the past 5 years, 6 new agents have been approved …

Background Patient characteristics and survival outcomes in randomized trials may be
different from those in real-life clinical practice. The objective of this study was to describe …

Background/Aim: Since the advent of targeted therapeutics, paradigms in metastatic renal
cell carcinoma (mRCC) treatment have changed. We investigated if efficacy and safety data …

The therapy of advanced (clear-cell) renal cell carcinoma (RCC) has recently experienced
tremendous changes. Several new treatments have been developed, with PD-1 immune …

There is a strong rationale for sequencing targeted therapy in metastatic clear cell renal
cancer. However the timing of the switch and the best agent to switch to remains unclear …